Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cytophage Technologies Ltd V.CYTO

Alternate Symbol(s):  CPTCF

Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.


TSXV:CYTO - Post by User

User Avatar Image
(2)
•••
  • Patent101X
Comment by Patent101on Jan 09, 2025 1:07pm
56 Views
Post# 36396387

RE:Bacteriophages are not proprietary

RE:Bacteriophages are not proprietary

 

Cytophage employs cocktails of genetically modified bacteriophages (example: 5 to 12 different phages). The modify the binding domains of their custom-designed "Frankenstein-phages" to precisely target specific bacteria.  

They have patent applications pending in the US, Canada, Europe, and Asia, all of which are publicly accessible for review—an impressive testament to their innovation pipeline.

Regarding human use, Cytophage has already achieved this critical milestone. Overcoming such a significant hurdle early on is a noteworthy achievement. Well done!

As a side note, phages are classified as "Generally Recognized as Safe" (GRAS) in the USA, and engineered phages are already being used commercially in various industries. In healthcare, companies like Adaptive Phage Therapeutics and Phico Therapeutics are exploring phage-based solutions for antibiotic-resistant infections. In the food industry, Intralytix and Micreos Food Safety lead the way with products targeting bacteria like Listeria and Salmonella. Additionally, in agriculture, companies like BiomX are developing phage therapies to protect crops from harmful bacteria.

It’s exciting to see Cytophage contributing to this growing field. Good luck to all!


<< Previous
Bullboard Posts
Next >>